Harrow Health, Inc. 11.875% Senior Notes due 2027
Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Stock Overview
Explore Harrow Health, Inc. 11.875% Senior Notes due 2027’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1.1B
P/E Ratio
-54.47
EPS (TTM)
N/A
ROE
-0.28%
HROWM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $26.48.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -54.47 and a market capitalization of 1.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Mark L. Baum
217
Nashville
2022